VTVT vTv Therapeutics Inc.

4.95
+0.05  (1%)
Previous Close 4.90
Open 4.91
Price To book 0.00
Market Cap 47.98M
Shares 9,693,000
Volume 10,836
Short Ratio 11.81
Av. Daily Volume 21,622

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17810272
  2. 8-K - Current report 17810016
  3. 8-K - Current report 17720672
  4. 8-K - Current report 17715673
  5. CT ORDER - Confidential treatment order 17714417

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released August 2016. Primary endpoint met.
TTP399 - AGATA
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
TTP273 - LOGRA
Type 2 Diabetes
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Data from Part A due early 2018. Part B due late 2018.
Azeliragon - STEADFAST
Mild Alzheimer’s disease

Latest News

  1. Corporate insiders have sold $4B in stock in 30 days; here's who's buying and selling in the Triad
  2. ETFs with exposure to vTv Therapeutics, Inc. : May 22, 2017
  3. vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
  4. VTv Therapeutics reports 1Q loss
  5. vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results
  6. ETFs with exposure to vTv Therapeutics, Inc. : April 5, 2017
  7. vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
  8. vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences
  9. vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
  10. vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher
  11. vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes
  12. New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego
  13. Can Agilent Technologies (A) Pull a Surprise in Q4 Earnings?
  14. vTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences
  15. ETF’s with exposure to vTv Therapeutics, Inc. : November 7, 2016
  16. vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights
  17. vTv Therapeutics to Present at Peptide Therapeutics Symposium